Corvus Pharmaceuticals, Inc. — Director's Dealing 2018

Dec 14, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Corvus Pharmaceuticals, Inc. (CRVS)
CIK: 0001626971
Period of Report: 2018-12-12

Reporting Person: Hunt Daniel W. (SVP, Chief Business Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-12-12	Stock Option (Right to Buy)	$5.94	A	50000	Disposed	2028-12-12	Common Stock (50000)	Direct

Footnotes

F1: The underlying shares subject to the option vest and become exercisable as to one-forty eighth (1/48th) of the shares subject to the option in successive, equal monthly installments measured from December 12, 2018, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.